Clinical Trial

Frontline Risk-Adapted Optimization of Novel Targeted Immunotherapy Evaluation in High-Risk MCL

Name: Frontline Risk-Adapted Optimization of Novel Targeted Immunotherapy Evaluation in High-Risk MCL — clinical trial record (NCT07569965)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: FRONTIER

Not Yet Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

FRONTIER is a prospective, single arm, open label, multi-center, Phase II study of MB-CART2019.1 (Zamtocabtagene Autoleucel) therapy as frontline consolidation for high-risk Mantle Cell Lymphoma (MCL) participants

Trial Details

NCT Number	NCT07569965
Lead Sponsor	Miltenyi Biomedicine GmbH Collaborators: National Heart, Lung, and Blood Institute (NHLBI), National Cancer Institute (NCI)
Conditions	Mantle Cell Lymphoma (MCL)
Enrollment	52 participants
Start Date	2026-09
Primary Completion	2029-09 (estimated)
Study Completion	2030-03 (estimated)
Updated on ClinicalTrials.gov	2026-05-06